Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
Oversubscribed Series A financing led by Cerberus Ventures, with participation from multiple new and existing investors, totals $33 million Syntis also awarded up to $5 million in non-dilutive grants from NIH Capital supports SYNT™ platform…